Ticker

Great Point Partners increased its APGE position by 70,000 shares in the fourth quarter; the estimated transaction value was $4.41 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by $16.15 million, reflecting both share purchases and price movement.

SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 9:10 a.m. E.T. Management will also attend the UBS Biotech Summit Miami, Catalyst for Change on Monday, March 9, 2026, and the Jefferies Biotech on the Beach…

Perceptive Advisors increased its Apogee Therapeutics position by 978,662 shares; the estimated trade value was $61.64 million (based on quarterly average prices). Meanwhile, the quarter-end position value rose by $122.20 million, including changes from both trading and price movements.

Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fifteen brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eight have issued a buy recommendation and three

Affinity Asset Advisors bought 61,500 shares of Apogee Therapeutics in the fourth quarter; the estimated transaction value was $3.87 million (based on quarterly average prices). Meanwhile, the quarter-end position value rose by $46.59 million, reflecting both trade and stock price movement.